Tak, Won Young http://orcid.org/0000-0002-1914-5141
Ryoo, Baek-Yeol
Lim, Ho Yeong
Kim, Do-Young
Okusaka, Takuji
Ikeda, Masafumi
Hidaka, Hisashi
Yeon, Jong-Eun
Mizukoshi, Eishiro
Morimoto, Manabu
Lee, Myung-Ah
Yasui, Kohichiroh
Kawaguchi, Yasunori
Heo, Jeong
Morita, Sojiro
Kim, Tae-You
Furuse, Junji
Katayama, Kazuhiro
Aramaki, Takeshi
Hara, Rina
Kimura, Takuya
Nakamura, Osamu
Kudo, Masatoshi
Article History
Received: 29 June 2018
Accepted: 17 August 2018
First Online: 10 September 2018
Compliance with ethical standards
:
: Won Young Tak has served as a compensated consultant/advisor for Bayer HealthCare Pharmaceuticals Inc., Gilead Science Korea Ltd., AbbVie Ltd., Ono Pharma Korea Co., Ltd., Eisai Korea Inc., and Bukwang Pharmaceutical Co., Ltd. He has also received research grant support from Samil Pharm Co., Ltd. as well as honoraria from Bayer Korea Ltd., MSD Korea Ltd., Gilead Science Korea Ltd., AbbVie Ltd., Samil Pharm Co., Ltd., and Yuhan Co., Ltd.Takuji Okusaka has received honoraria from Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., Bayer Yakuhin, Ltd., Yakult Honsha Co., Ltd., Nobelpharma Co., Ltd., FUJIFILM RI Pharma Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Nippon Chemiphar Co., Ltd., Celgene, K.K., Chugai Pharmaceutical Co., Ltd., Bristol-Myers K.K., Eisai Co., Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., Daiichi Sankyo Co., Ltd., and MSD, K.K. He has also served as a compensated consultant/advisor for Dainippon Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd. Furthermore, he has received research grant support from Eli Lilly Japan K.K., Eisai Co., Ltd., Novartis Pharma K.K., Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Kowa Company, LTD, Kyowa Hakko Kirin Co., Ltd., Merck Serono Co., Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., AstraZeneca K.K., Dainippon Sumitomo Pharma Co., Ltd., Nano Carrier Co., Ltd., and Baxter.Masafumi Ikeda has received research grants from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult Honsha, Taiho Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria Pharmaceutical, Baxalta Japan Limited, Chugai Pharmaceutical, Bristol-Myers Squibb, Merck Serono, Kowa, Nano Carrier, ASLAN Pharmaceuticals, Novartis Pharma, and Takara Bio. He has also received honoraria from Novartis Pharma, Bayer Yakuhin, Bristol-Myers Squibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli Lilly Japan, Daiichi-Sankyo, Yakult Honsha, Otsuka Pharmaceutical, Nobelpharma, Sumitomo Dainippon Pharma, and Teijin Pharma. Furthermore, he has received consulting fees from Nano Carrier, Bayer Yakuhin, Eisai, Kyowa Hakko Kirin, Novartis Pharma, Shire, MSD, Bristol-Myers Squibb, Teijin Pharma, and Daiichi-Sankyo.Manabu Morimoto has received honoraria from Bayer, Dainippon-Sumitomo, Eisai, and Nippon-Kayaku as well as research grant support from Bayer, Yakuruto, Shionogi, Eli Lilly, Kyowa-Hakko-Kirin, and Kowa.Junji Furuse has received honoraria from Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, Sumitomo Dainippon, Eli Lilly Japan, Astellas Pharma, Ono Pharmaceutical, Pfizer, Bayer Yakuhin, Novartis, Merck Serono, Takeda, Eisai, MSD, Shionogi Pharma, J-Pharma, Daiichi Sankyo, Mochida Pharmaceutical Co. Ltd., Nippon Kayaku, EA Pharma, Sawai Pharmaceutical Co, and Teijin Pharma. He has also served as a compensated consultant/advisor for Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, Sumitomo Dainippom, Eli Lilly Japan, Astellas Pharma, Ono Pharmaceutical, Pfizer Bayer Pharmaceutical, Novartis, Merck Serono, Takeda, Eisai, MSD, Shionogi Pharma, J-Pharma, Daiichi Sankyo, Kyowa Hakko Kirin, Sanofi, Sandoz, Otsuka, Zeria Pharmaceutical, Fujifilm, AstraZeneca, Asahi Kasei and Shire. Furthermore, he has received research grant support from J-Pharma, Taiho Pharmaceutical, Sumitomo Dainippom, Janssen, Daiichi Sankyo, MSD, Yakult Honsha, Takeda, Chugai Pharma, Ono Pharmaceutical, Astellas Pharma, Zeria Pharmaceutical, Novartis, NanoCarrier, Shionogi Pharma, Onco Therapy Science, Eli Lilly Japan, Bayer, Bristol-Myers Squibb, Merck Serono, Kyowa Hakko Kirin, Eisai, Mochida Pharmaceutical Co. Ltd., Baxalta and Sanofi.Kazuhiro Katayama has received speaker’s bureau honorarium from Ajinomoto, Otsuka, Chugai, MSD, Bristol-Myers, Daiichi-Sankyo, Bayer, Nobelpharma Co., Ltd. He has also received research grant support from Bayer, Asuka, Kowa, and Bristol-Meyers.Masatoshi Kudo has received honoraria from Bayer, Eisai, MSD, and Ajinomoto. He has served as a compensated consultant/advisor for Bayer, Eisai, Kowa, MSD, BMS, Chugai, and Taiho. Furthermore, he has received research grant support from Daiichi Sankyo, Medico’s Hirata, Otsuka, Taiho, Astellas Pharma, Chugai, Abbvie, Bristol-Myers Squibb, Takeda, MSD, Eisai, Sumitomo Dainippon, and Bayer.Rina Hara has stock ownership of Yakult. Rina Hara, Takuya Kimura, and Osamu Nakamura are employees of Yakult.No potential conflicts of interest were disclosed by the other authors.
: This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.